報價延遲最少15分鐘:2025/09/18 02:53 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.32 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.30/-2.14
|
|
企業價值
14.76M
|
| 資產負債 |
|
每股賬面淨值
-0.25
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/09/18 02:53 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan. |
